ANIP ANI Pharmaceuticals Dashboard

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Company profile

Ticker

ANIP

Exchange

NASDAQ

Website

www.anipharmaceuticals.com/

CEO

Patrick Walsh

Incorporated

Delaware

Location

Minnesota

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC

SEC CIK

0001023024

Corporate docs

Articles of Incorporation & Bylaws

IRS number

582301143

ANIP stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

ANI Pharmaceuticals Acquires New Drug Applications For OXISTAT Lotion, VEREGEN Ointment And Pandel Cream And Abbreviated NDA For ApexiCon E Cream

6 Apr 21

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced that it has acquired the new drug applications ("NDAs") for OXISTAT® Lotion, VEREGEN® Ointment, and

The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data

9 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 8)

ANI Pharmaceuticals Q4 Adj. EPS $0.80 Misses $0.94 Estimate, Sales $57.30M Beat $54.27M Estimate

9 Mar 21

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $0.80 per share which missed the analyst consensus estimate of $0.94 by 14.89 percent. This is a 25.93 percent decrease over earnings of $1.08 per share

ANI Pharmaceuticals To Acquire Novitium Pharma For $163.5M

9 Mar 21

Earnings Scheduled For March 9, 2021

9 Mar 21

Press releases

Pro users get this 30m faster

ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs

6 Apr 21

-- Accretive transaction in line with growth strategy laid out for Branded Products business -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced that it has acquired the new drug applications ("NDAs")

ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results; Company Positioned for Sustainable Future Growth

9 Mar 21

-- Fourth quarter 2020 net revenues of $57.3 million; net loss of $3.6 million and diluted loss per share of $0.30 -- -- Fourth quarter adjusted non-GAAP EBITDA of $17.2 million and adjusted non-GAAP diluted eps of

ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business

9 Mar 21

Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 Expands Brand Portfolio with Addition of 505(b)(2) Pipeline and Enhances Scale of CDMO Business Purchase Price of

ANI Pharmaceuticals, Inc. to Host Earnings Call

9 Mar 21

ANI Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Feb 21

Calendar

11 Mar 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart ANIP financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	12.87M	12.87M	12.87M	12.87M	12.87M	12.87M
Cash burn (monthly)	3.35M	4.54M	794K	1.94M	1.9M	(positive/no burn)
Cash used (since last report)	11.49M	15.6M	2.73M	6.65M	6.54M	n/a
Cash remaining	1.38M	-2.73M	10.14M	6.22M	6.33M	n/a
Runway (months of cash)	0.4	-0.6	12.8	3.2	3.3	n/a

Beta Read what these cash burn values mean

Recent insider trades

ANIP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Apr 21	Carey Stephen P.	Common Stock	Payment of exercise	Dispose F	No	No	33.69	612	20.62K	115,542
6 Apr 21	Marken James G.	Common Stock	Payment of exercise	Dispose F	No	No	33.69	337	11.35K	116,199
31 Mar 21	Carey Stephen P.	Common Stock	Payment of exercise	Dispose F	No	No	36.14	508	18.36K	116,154
31 Mar 21	Marken James G.	Common Stock	Payment of exercise	Dispose F	No	No	36.14	278	10.05K	116,536
29 Mar 21	Schrepfer Robert W	Common Stock	Payment of exercise	Dispose F	No	No	32.68	5,566	181.9K	87,477
29 Mar 21	Carey Stephen P.	Common Stock	Payment of exercise	Dispose F	No	No	32.68	953	31.14K	116,662
29 Mar 21	Marken James G.	Common Stock	Payment of exercise	Dispose F	No	No	32.68	524	17.12K	116,814

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ANIP institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Sun Pharmaceutical Industries • Evoke Pharma • Perrigo • Mylan II B.V. • Amneal Pharmaceuticals

Management Discussion

In July 2020, we acquired an ANDA and certain related inventories from a private company for total consideration of $4.3 million. The transaction was funded using cash on hand.
In May 2020, we entered into an agreement with a private company to purchase an ANDA and API for one currently marketed generic drug product and certain API for $0.2 million. The transaction was funded using cash on hand.
In January 2020, we completed the acquisition of the U.S. portfolio of 23 generic products and API and finished goods related to certain of those products from Amerigen Pharmaceuticals, Ltd. ("Amerigen") for a purchase consideration of $56.8 million and up to $25.0 million in contingent payments over the next three years. The product portfolio at the time of the acquisition included ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded using cash on hand and $15.0 million in borrowings under our $75.0 million Revolver.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrual, agree, agreed, al, Ampersand, Amphetamine, anniversary, anticompetitive, antitrust, appointed, area, argument, Aspartate, assignee, augment, aware, Azar, Baltimore, BBA, Bexarotene, bidding, Biden, biopharmaceutical, Biotech, biotechnology, Bipartisan, Bird, Blueprint, Boehringer, boomer, Budget, built, bulk, burgeoning, Bystolic, Cabaret, CDMO, CEO, Chad, Chali, Citrate, Colorado, colorectal, compliant, composition, Congressional, consequential, constitutionality, contact, counter, creative, defect, departed, Department, departure, Dextroamphetamine, diminish, disagreement, disgorgement, distancing, distracted, domain, downstream, Dr, easing, economy, elapsed, empowered, encompassing, encourage, encouraged, Eq, Eshhar, Esjay, Europe, European, explore, Ezetimibe, feasible, Florida, footprint, Forest, frame, fringe, Gassert, gastrointestinal, Gilead, goal, grew, GTM, guideline, heard, heightened, Hetero, HHS, Hightower, incentivize, induce, inducement, Ingelheim, inorganic, instance, Israeli, Jeanne, joined, Judge, judicial, kidney, Kite, Koepsel, Kroger, Lalwani, led, length, lengthy, Lineberry, liver, Lovette, Master, MD, MDL, medicinal, Memantine, mEq, Mexico, Mexiletine, Miglustat, mission, Monohydrate, month, MPIC, multidistrict, Muthusamy, NaN, negligence, negligent, NEO, Nikhil, Nile, Novitium, nuisance, onboarding, oncology, outbreak, outpatient, Paliperidone, pandemic, Paragraph, pendency, Penicillamine, perspective, Pfizer, PIPE, placement, plaintiff, pocket, Potassium, premise, Presidential, programmatic, prominent, province, purposeful, quantified, quarantine, reached, recalculated, recalculating, recycling, regional, reinstituted, remand, repaid, replead, resubmission, resume, reuse, reward, Robin, Rosenberg, RTF, Saccharate, salary, sanitation, scrutiny, sensitivity, Shanmugam, shift, Simvastatin, situation, sNDA, sound, Southern, sparsely, SPI, spread, staggered, static, stomach, Sulfamethoxazole, territory, Thoma, Thorappadi, timeline, Tolterodine, Torrent, trailing, training, transparency, travel, treble, Trimethoprim, Tripartite, turnover, unbilled, undisclosed, undue, University, unprecedented, unreasonable, Vijayaraj, visited, voluntarily, waived, Walgreen, Watson, widespread, withholding, world, worsen, worsening, Zantac, Zelig

Removed: absorbed, activator, acute, adjunct, adjunctive, adjuvant, adult, advancing, agent, allegedly, alpha, amortizing, analog, androgen, angina, angiotensin, annualization, annualized, antagonist, antihypertensive, anxiety, APIC, Apo, appetite, aromatase, arrhythmia, ascending, ascribed, assigned, Atropine, Australia, back, backlog, batch, bipolar, blocker, blood, boom, bowel, brain, breast, bringing, capsule, carcinoma, cardiovascular, castration, cautionary, chronic, collectability, collection, concomitantly, congestive, consecutive, construed, continuity, conventional, cough, counterparty, cream, curb, daytime, decreasing, deducting, define, diabetic, diarrhea, diet, Diphenoxylate, discounted, discrete, disorder, distal, diuretic, documented, dyslipidemia, earlier, elevated, embedded, emerge, entirety, Etodolac, exceeding, exhaustive, extinguishment, fatal, feeling, Flecainide, fluctuated, fluid, formal, front, funding, gastric, gastroesophageal, glaucoma, Gulfport, headache, heal, heart, heartbeat, heartburn, hemorrhage, historic, Holmdel, hypercholesterolemia, hypertension, hypertriglyceridemia, hypertrophic, IDT, implied, incidence, inclusion, incurrence, Indapamide, indenture, indexed, inflammatory, inhibitor, inInternal, intensity, interfere, intermediate, intraocular, irregular, ischemic, leasing, Louisiana, lowering, LP, luteinizing, Maleate, manic, meal, measurable, Media, met, metastatic, migraine, mild, Mississippi, myocardial, nausea, negotiate, neurological, Nilutamide, Nimodipine, nonfatal, NYHA, object, occupationally, ocular, Orange, Overlay, oxycodone, pain, Pennsylvania, percent, peroxisome, Pindolol, pose, postmenopausal, preceding, preoperatively, privately, proliferator, Propafenone, proportion, propriety, proscribed, prostate, proved, pruritic, putting, receptor, rectal, recurrent, reflux, reimbursable, reintroduce, renamed, reorganization, replaced, represented, repurchased, revaluation, revise, rheumatoid, rule, ruptured, salt, satisfaction, seasonal, seasonality, secondary, simultaneously, socially, stroke, subaortic, subarachnoid, supplementary, surgery, surgical, swelling, symptomatic, synthetically, systematically, TG, theInternal, tolerance, transverse, treat, ulcerative, underwriting, unpaid, Unregistered, unwinding, update, vomiting, warrant, writing, yielding

From filing 10-K 2020 FY